Aytu BioPharma Reports Q2 2026 Earnings with EXXUA Launch Insights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy AYTU?
Source: seekingalpha
- EXXUA Launch Progress: Aytu BioPharma's EXXUA, the first FDA-approved 5HT1a agonist, has been prescribed in 27 states by over 100 physicians, indicating strong market demand and potential for sales growth.
- Revenue Performance: The company reported net revenue of $15.2 million for Q2, a decline from $16.2 million year-over-year, yet the ADHD portfolio's $13.2 million revenue demonstrates resilience, suggesting stability in a competitive market.
- Gross Margin Changes: Gross margin for the quarter was reported at 63.5%, down from 66.5% last year, primarily due to transition-related expenses and an inventory write-down of approximately $600,000, impacting overall profitability.
- Future Outlook: The company anticipates a slight increase in EXXUA net revenue in the March 2026 quarter, targeting breakeven at $17.3 million per quarter, reflecting management's confidence in future growth despite market challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AYTU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AYTU
Wall Street analysts forecast AYTU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AYTU is 9.33 USD with a low forecast of 7.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.390
Low
7.00
Averages
9.33
High
13.00
Current: 2.390
Low
7.00
Averages
9.33
High
13.00
About AYTU
Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aytu BioPharma Reports Q2 2026 Earnings with EXXUA Launch Insights
- EXXUA Launch Progress: Aytu BioPharma's EXXUA, the first FDA-approved 5HT1a agonist, has been prescribed in 27 states by over 100 physicians, indicating strong market demand and potential for sales growth.
- Revenue Performance: The company reported net revenue of $15.2 million for Q2, a decline from $16.2 million year-over-year, yet the ADHD portfolio's $13.2 million revenue demonstrates resilience, suggesting stability in a competitive market.
- Gross Margin Changes: Gross margin for the quarter was reported at 63.5%, down from 66.5% last year, primarily due to transition-related expenses and an inventory write-down of approximately $600,000, impacting overall profitability.
- Future Outlook: The company anticipates a slight increase in EXXUA net revenue in the March 2026 quarter, targeting breakeven at $17.3 million per quarter, reflecting management's confidence in future growth despite market challenges.
See More
Aytu BioPharma AYTU Q2 2026 Earnings Transcript
See More
Aytu BioPharma Q2 Earnings Analysis
- Earnings Performance: Aytu BioPharma reported a Q2 GAAP EPS of -$1.05, missing expectations by $0.45, indicating challenges in profitability that may affect investor confidence.
- Revenue Insights: The company generated $15.2M in revenue, a 6.3% year-over-year decline, yet exceeded market expectations by $3.03M, suggesting a resilient market demand despite challenges.
- Investment Strategy: Aytu BioPharma plans to invest $10M in the launch of EXXUA, aiming to enhance the performance of its ADHD product line and drive future revenue growth.
- Breakeven Target: The company has set a breakeven quarterly revenue target of $17.3M, indicating that achieving this goal will be crucial for the success of its future strategic initiatives.
See More
Aytu BioPharma to Announce Q2 Earnings on February 3rd
- Earnings Announcement: Aytu BioPharma (AYTU) is set to release its Q2 earnings report on February 3rd after market close, with a consensus EPS estimate of -$0.60, indicating ongoing challenges in profitability.
- Revenue Expectations: Analysts project quarterly revenue of $12.17 million for Aytu, yet the company has not seen any upward revisions in revenue estimates over the past three months, reflecting concerns about its sales growth.
- EPS Revision Trends: Over the last three months, EPS estimates have experienced two upward revisions and no downward adjustments, suggesting a slight increase in analyst confidence regarding the company's future profitability, although the overall outlook remains negative.
- Revenue Revision Trends: In contrast to EPS, revenue estimates have seen three downward revisions during the same period, highlighting Aytu's ongoing difficulties in achieving revenue growth, which could impact its market performance and investor confidence.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Nutex Health Rises 21% in After-Hours Trading Following Revenue Increase; Biotech Competitors Also See Gains on Tuesday
Nutex Health's Performance: Nutex Health Inc. saw a significant after-hours surge of 20.97% to $120.00 following a quarterly report that revealed a net loss of $17.7 million but a remarkable 220.7% increase in revenue year-over-year to $244.0 million.
Bullfrog AI Holdings Update: Bullfrog AI Holdings, Inc. gained 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of its upcoming technical presentation at the AI Drug Discovery & Development Summit 2025.
Clearside Biomedical's Recovery: Clearside Biomedical, Inc. rose 6.51% to $3.27 after reporting a narrower net loss of $5.97 million, although its revenue fell sharply to $201 thousand from $1.04 million a year ago.
Aytu BioPharma and OKYO Pharma Developments: Aytu BioPharma, Inc. climbed 8.91% to $2.20 after reporting a first-quarter net income increase, while OKYO Pharma Limited edged up 2.44% to $2.18, preparing for a presentation on its investigational drug candidate for neuropathic corneal pain.
See More
Aytu BioPharma Reports Q2 2026 Earnings with EXXUA Launch Insights
- EXXUA Launch Progress: Aytu BioPharma's EXXUA, the first FDA-approved 5HT1a agonist, has been prescribed in 27 states by over 100 physicians, indicating strong market demand and potential for sales growth.
- Revenue Performance: The company reported net revenue of $15.2 million for Q2, a decline from $16.2 million year-over-year, yet the ADHD portfolio's $13.2 million revenue demonstrates resilience, suggesting stability in a competitive market.
- Gross Margin Changes: Gross margin for the quarter was reported at 63.5%, down from 66.5% last year, primarily due to transition-related expenses and an inventory write-down of approximately $600,000, impacting overall profitability.
- Future Outlook: The company anticipates a slight increase in EXXUA net revenue in the March 2026 quarter, targeting breakeven at $17.3 million per quarter, reflecting management's confidence in future growth despite market challenges.
See More
Aytu BioPharma AYTU Q2 2026 Earnings Transcript
See More
Aytu BioPharma Q2 Earnings Analysis
- Earnings Performance: Aytu BioPharma reported a Q2 GAAP EPS of -$1.05, missing expectations by $0.45, indicating challenges in profitability that may affect investor confidence.
- Revenue Insights: The company generated $15.2M in revenue, a 6.3% year-over-year decline, yet exceeded market expectations by $3.03M, suggesting a resilient market demand despite challenges.
- Investment Strategy: Aytu BioPharma plans to invest $10M in the launch of EXXUA, aiming to enhance the performance of its ADHD product line and drive future revenue growth.
- Breakeven Target: The company has set a breakeven quarterly revenue target of $17.3M, indicating that achieving this goal will be crucial for the success of its future strategic initiatives.
See More
Aytu BioPharma to Announce Q2 Earnings on February 3rd
- Earnings Announcement: Aytu BioPharma (AYTU) is set to release its Q2 earnings report on February 3rd after market close, with a consensus EPS estimate of -$0.60, indicating ongoing challenges in profitability.
- Revenue Expectations: Analysts project quarterly revenue of $12.17 million for Aytu, yet the company has not seen any upward revisions in revenue estimates over the past three months, reflecting concerns about its sales growth.
- EPS Revision Trends: Over the last three months, EPS estimates have experienced two upward revisions and no downward adjustments, suggesting a slight increase in analyst confidence regarding the company's future profitability, although the overall outlook remains negative.
- Revenue Revision Trends: In contrast to EPS, revenue estimates have seen three downward revisions during the same period, highlighting Aytu's ongoing difficulties in achieving revenue growth, which could impact its market performance and investor confidence.
See More
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
- Investor Attention: As the earnings season unfolds, mid to low market capitalization healthcare stocks are drawing investor attention due to their strong earnings momentum, indicating growing market confidence in this sector.
- Analyst Expectations: The EPS Revision Grade reflects the trend in analyst earnings estimates, with A+ ratings indicating optimistic projections for future performance, potentially driving stock prices higher.
- List of A+ Rated Stocks: Currently, companies such as Aldeyra Therapeutics, Altimmune, Annovis Bio, and Assertio Holdings have received A+ EPS Revision Grades, showcasing their strong performance in the eyes of analysts.
- Market Strategy Impact: These A+ rated healthcare stocks are likely to attract more investor interest, potentially triggering positive sentiment towards the healthcare sector as a whole, thereby enhancing the performance of related ETFs.
See More
Nutex Health Rises 21% in After-Hours Trading Following Revenue Increase; Biotech Competitors Also See Gains on Tuesday
Nutex Health's Performance: Nutex Health Inc. saw a significant after-hours surge of 20.97% to $120.00 following a quarterly report that revealed a net loss of $17.7 million but a remarkable 220.7% increase in revenue year-over-year to $244.0 million.
Bullfrog AI Holdings Update: Bullfrog AI Holdings, Inc. gained 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of its upcoming technical presentation at the AI Drug Discovery & Development Summit 2025.
Clearside Biomedical's Recovery: Clearside Biomedical, Inc. rose 6.51% to $3.27 after reporting a narrower net loss of $5.97 million, although its revenue fell sharply to $201 thousand from $1.04 million a year ago.
Aytu BioPharma and OKYO Pharma Developments: Aytu BioPharma, Inc. climbed 8.91% to $2.20 after reporting a first-quarter net income increase, while OKYO Pharma Limited edged up 2.44% to $2.18, preparing for a presentation on its investigational drug candidate for neuropathic corneal pain.
See More
